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Summary
 
Leucine-based signals in the cytoplasmic tail of invariant chain (Ii) control targeting of newly
synthesized major histocompatibility complex class II molecules to the endocytic pathway for
acquisition of antigenic peptides. Some protein determinants, however, do not require Ii for
effective class II presentation, although endocytic processing is still necessary. Here we demon-
strate that a dileucine-based signal in the cytoplasmic tail of the class II 
 
b
 
 chain is critical for this
Ii-independent presentation. Elimination or mutation of this signal reduces the rate of re-entry
of mature surface class II molecules into the endocytic pathway. Antigen presentation con-
trolled by this signal does not require newly synthesized class II molecules and appears to in-
volve determinants requiring only limited proteolysis for exposure, whereas the opposite is true
for Ii-dependent determinants. This demonstrates that related leucine-based trafficking signals
in Ii and class II control the functional presentation of protein determinants with distinct pro-
cessing requirements, suggesting that the peptide binding sites of newly synthesized versus ma-
ture class II molecules are made available for antigen binding in distinct endocytic compartments
under the control of these homologous cytoplasmic signals. This permits capture of protein frag-
ments produced optimally under distinct conditions of pH and proteolytic activity.
 
M
 
HC class II molecules present to CD4
 
1
 
 T cells pep-
tides derived from proteins entering the endosomal–
phagosomal system (1, 2). Invariant chain (Ii)
 
1
 
 aids in as-
sembly and transport of newly synthesized class II molecules
and also protects the class II binding site from either im-
proper folding or premature interaction with protein li-
gands in the secretory pathway (3). This same type II mem-
brane protein also contains a pair of leucine-based signals in
its cytoplasmic tail that promote its trafficking and that of
associated newly synthesized class II molecules through
early endocytic compartments to dense organelles of the
endocytic pathway (4–10). Class II capture of antigenic frag-
ments in these class II–rich organelles (MIIC) requires pro-
teolytic removal of associated Ii (11), particularly of the
class II–associated invariant peptide (CLIP) fragment (12,
13) whose replacement in the binding site by antigenic pep-
tides is facilitated by the MHC-encoded DM molecule
(14–16).
Although this general scheme of Ii-regulated class II syn-
thesis, trafficking, and antigen capture is supported by nu-
merous studies using transformed cell lines, transfected
cells, and cells of wild-type and Ii–deficient mice, not all
peptide determinants require Ii for effective presentation,
although they still require processing in acidic compartments
(17–21). Distinct determinants in even a single protein an-
tigen (hen egg lysozyme, HEL) can show differential de-
pendence on Ii for their effective presentation (19). Other
studies have demonstrated that some antigenic determi-
nants are dependent on new protein synthesis or secretory
pathway export for their presentation, whereas others are
not (22–25), providing a parallel to the Ii data in terms of
the involvement of newly synthesized (Ii-associated) versus
mature class II (Ii-free) in effective presentation of these
different antigenic fragments.
These observations of Ii-independent, endosomal pro-
cessing–dependent presentation of some antigenic determi-
nants are consistent with the accumulation of class II pro-
teins in intracellular vesicles with the characteristics of late
endosomes/lysosomes in some cells lacking Ii coexpression
(26–28). Functional studies have also shown that truncation
of the class II 
 
b
 
 chain cytoplasmic tail affects antigen pre-
sentation to some autoreactive T cell hybridomas even by
cells producing Ii (29), although other determinants remain
well presented by the same mutant class II molecules (30).
In experiments with intact influenza particles, truncation of
 
1
 
Abbreviations used in this paper:
 
 BFA, brefeldin A; CLIP, class II–associated
invariant chain peptide; HEL, hen egg lysozyme; Ii, invariant chain;
MIIC, class II–rich organelles; RBL, rat basophil leukemia cell.
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the class II 
 
a
 
 or 
 
b
 
 cytoplasmic tails selectively interferes
with presentation of a hemagglutinin determinant whereas
a matrix protein-derived determinant is instead dependent
on Ii for presentation (31). These studies revealed a correla-
tion between hemagglutinin presentation and the involve-
ment of the class II cytoplasmic tails in entry of mature sur-
face class II into the endocytic pathway. Similarly, Smiley
et al. have demonstrated in a mouse model system that the
cytoplasmic tails of class II molecules play a key role in the
presentation of some antigenic determinants (32).
These various findings suggest that two distinct pathways
for class II–dependent antigen presentation exist, and imply
that separate protein localization signals in the cytoplasmic
tails of Ii and class II play important roles in these events.
The identity of the localization signal(s) in class II chains
has not been established, although Smiley et al. have hy-
pothesized that conserved dileucines in the class II 
 
b
 
 chain
tail are likely to be involved (32). In addition, the role of
such localization signals in class II has not been directly com-
pared to that of Ii signals in presenting different antigenic
determinants from a single protein molecule. Finally, little
information is available on what predisposes presentation of
different determinants within a given protein antigen to
dependence on one or the other of these pathways. In the
present study, we have used the well-characterized HEL
antigenic model (33) to examine these issues. We demon-
strate that the dileucine-containing sequence in the class II
 
b
 
 chain noted by Smiley et al. (32) is critical for Ii-inde-
pendent presentation of two HEL determinants, whereas a
third determinant in the same protein requires the tail sig-
nals in Ii for its effective presentation. In combination with
earlier observations, our data support a model of class II
presentation involving (
 
a
 
) Ii-dependent capture of buried
antigenic determinants in lysosome-related, highly pro-
teolytic compartments by newly synthesized class II mole-
cules and (
 
b
 
) 
 
b
 
 chain–tail dependent antigen capture of
more superficial determinants in less proteolytic (early) en-
docytic organelles by mature, recycling class II. These two
pathways together provide a mechanism for optimal pre-
sentation of the multiple determinants often contained in
proteins entering the endocytic pathway.
 
Materials and Methods
 
Reagents.
 
HEL (cat No. L6876, lot No. 89F8275), diethyl-
amino-ethyl–dextran, chloroquine, and dimethyl sulfoxide were
obtained from Sigma Chemical Co (St. Louis, MO). LPS was from
DIFCO (3122-25-8; Detroit, MI), recombinant murine IFN-
 
g
 
from PharMingen (San Diego, CA), brefeldin A (BFA) from Epi-
centre Technologies Corp. (Madison, WI), leupeptin from Boeh-
ringer Mannheim (Indianapolis, IN), and G418 (Geneticin) from
GIBCO (Gaithersburg, MD). The peptides HEL 46-61 (NTDG-
STDYGILQINSR), HEL 34-45 (FESNFNTQATNR), and HEL
116-129 (KGTDVQAWIRGCRL) were synthesized and puri-
fied by HPLC before use by the National Institute of Allergy and
Infectious Diseases Peptide Synthesis Facility (Rockville, MD).
 
Constructs.
 
The cDNA constructs coding for the wild-type 
 
a
 
or 
 
b
 
 chain of A
 
k
 
 in the plasmid CDM8 (34) and the cDNA cod-
ing for murine Ii31 in the plasmid pcEXV3 have been previously
 
described (35). A construct coding for the 
 
b
 
 chain of A
 
k
 
 with an 18
amino acid deletion at the COOH-terminus was made by placing
a stop codon after the codon encoding isoleucine 220, as de-
scribed elsewhere (29). The construct was placed into the expres-
sion plasmid vector pCDL-SR (36), provided by Dr. J. Bonifa-
cino (National Institute of Child Health and Development, National
Institutes of Health). The 
 
b
 
 chain with this COOH-terminal 18
amino acid deletion is designated as 
 
b
 
CT18. A construct coding
for a 
 
b
 
 chain with the cytoplasmic leucines at positions 236 and
237 each changed to alanine was made by oligonucleotide-directed
mutagenesis using PCR, and cloned into the pCDL-SR vector.
The 5
 
9
 
 primer was 5
 
9
 
 GTC AGA GCT CGA GTG TGC CTT
AGA GAT GGC TC 3
 
9
 
 and the 3
 
9
 
 primer was 5
 
9
 
 GAG CAC
CAG ATC TCA CTG AGC TGC CCC TGC TGG AGG
AGG GCC ACG AGG TCC 3
 
9
 
; mutagenesis was performed as
described (37). The resultant mutant 
 
b
 
 chain was designated as
 
b
 
CTAA. The sequences of all constructs were confirmed as cor-
rect using an automated DNA sequencer.
 
Transient Transfection.
 
Cos 7.2 cells were transiently trans-
fected with DNA of the cDNA constructs coding for the 
 
a
 
 and 
 
b
 
chain of A
 
k
 
 alone (3 
 
m
 
g each) or together with DNA for the cDNA
coding for murine Ii31 (10 mg), using a diethyl-amino-ethyl–
dextran method as previously reported (38).
 
Stable Transfectants.
 
Rat basophil leukemia cells (RBL)-5 were
stably transfected by electroporation with cDNA constructs coding
for the following combinations: 
 
a
 
/
 
b
 
, 
 
a
 
/
 
b
 
CT18, and 
 
a
 
/
 
b
 
CTAA,
with or without DNA for the construct encoding mIi31, using a
modified procedure from Engel et al. (36). 18 
 
m
 
g of DNA encod-
ing each chain of class II and 2 
 
m
 
g of pfneo (39) conferring resis-
tance to G418 were used for each electroporation. In the case of
Ii cotransfection, an additional 54 
 
m
 
g of DNA encoding Ii was
added. Transfected cells expressing the desired proteins were
cloned by limiting dilution.
 
FACS
 
Ò
 
 Staining.
 
The A
 
k
 
 expression level on transfectants
was measured by staining the surface using a saturating amount of
H116.32 antibody (40) on ice for 30 min. A FITC-conjugated
rabbit anti–mouse IgG (Jackson Laboratory, Bar Harbor, ME)
was used to detect the bound H116.32. Ii expression by the trans-
fectants was measured by intracellular staining with IN-1 (41) and
an FITC-conjugated goat anti–rat IgG (Jackson Laboratory). The
fluorescence intensity was measured on a FACScan
 
Ò
 
 flow cytometer
(Becton-Dickinson, Mountain View, CA). Transfectants with
comparable levels of surface class II and intracellular Ii in appro-
priate combinations were chosen for use in functional experi-
ments.
 
Antigen Presentation Using B Cells and M
 
F
 
s as APCs.
 
Single cell
suspensions from the spleens of CBA mice (Jackson Laboratory;
8–10 wk old, female) were made and red blood cells removed us-
ing ammonium chloride-potassium lysing buffer (Biofluids Inc.,
Rockville, MD). The splenocytes were cultured for 2 d in the
presence of 10 
 
m
 
g/ml LPS in RPMI medium containing 10%
FCS. The B cell blasts were then harvested and used as APCs. For
M
 
F
 
 preparation, CBA mice were injected intraperitoneally with
4 ml thioglycollate (National Institutes of Health Media Unit,
Bethesda, MD) and 4 d later, the exudate M
 
F
 
s were harvested by
washing the peritoneal cavity with ice-cold PBS. The exudate
cells were incubated in the wells of 96-well plates for 2 d in com-
plete RPMI 1640 medium containing 20 U/ml of murine IFN-
 
g
 
.
The IFN-
 
g
 
 activated M
 
F
 
s (IFN-
 
g
 
 M
 
F
 
s) were then used without
harvesting as APCs. In the antigen presentation assay, the B cell
blast or M
 
F
 
 APCs were pulsed with various concentrations of in-
tact HEL antigen for 6 h, and then fixed with 1% paraformalde-
hyde for 20 min followed by neutralization with 0.1 M glycine. 
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The fixed APCs pulsed with antigen (5 
 
3
 
 10
 
4
 
 cells/well) were
mixed with antigen-specific T cell hybridomas (5 
 
3
 
 10
 
4
 
 cells/well)
in a total volume of 200 
 
m
 
l in complete RPMI medium contain-
ing 2-ME. The cultures were incubated for 18–24 h and IL-2
production in the supernatant was measured by ELISA. The hy-
bridoma 3A9.1 specific for HEL epitope 46-61 was from Dr. Paul
Allen (Washington University, St. Louis, MD), and hybridomas
3B11.1 and 1B9.1 specific for HEL 34-45 and 116-129 respec-
tively were provided by Dr. L. Adorini (Roche Milano Ricerche,
Milan, Italy). For inhibition of antigen presentation, APCs were
pretreated with various concentrations of BFA for 15 min, chlo-
roquine for 30 min, or leupeptin for 2 h before HEL was added.
All APCs were then pulsed with 50 
 
m
 
M of HEL for 6 h in the
continued presence of inhibitor before fixation and addition to T
cells. Presentation of peptide was also assessed in parallel by add-
ing the indicated concentration of peptide to the cells for the
same 6-h period before washing and fixing.
 
Antigen Presentation Using Transfectants.
 
COS or RBL trans-
fectants were seeded onto 96-well plates at 5 
 
3
 
 10
 
4
 
 cells/well in
complete RPMI medium. HEL was added to the cells at various
concentrations followed by T cell hybridomas (5 
 
3
 
 10
 
4
 
/well).
The cultures were incubated at 37
 
8
 
C for 18 to 24 h and IL-2
measured in the supernatants. No fixation was used for presenta-
tion assays with these transfectants.
 
IL-2 ELISA.
 
The IL-2 level in culture supernatants was
measured by sandwich ELISA performed as previously described
(42). Under these conditions, the assay is linear to an OD of 
 
z
 
3.
Absolute levels of IL-2 produced in the various experiments were
generally between 10 and 100 U/ml.
 
Immunofluorescence Microscopy and Class II Internalization As-
say.
 
To evaluate internalization of surface class II, a modified
version of the procedure described by Roche et al. (43) was used.
Cells were grown on coverslips, washed twice with cold, com-
plete DMEM, and reacted with saturating amounts of 10-2.16
antibody for 2 h on ice to ensure monovalent binding. Cells were
then washed extensively to remove unbound antibody. Washed
cells were either left at 4
 
8
 
C or warmed to 37
 
8
 
C for various peri-
ods of time extending up to 150 min. After the appropriate time
interval, the cells were fixed with 10% paraformaldehyde for 10
min at room temperature, permeabilized with 0.2% saponin for
30 min, and then blocked with 2% BSA at 4
 
8
 
C overnight. Sam-
ples were then washed with PBS and stained using rabbit anti–mouse
IgG antibodies conjugated with FITC (Jackson Laboratory). To
exclude the possible class II–independent uptake of antibody into
endocytic structures, untransfected RBLs were treated in the same
manner. Coverslips bearing stained cells were mounted and ana-
lyzed using a confocal microscope (MRC1024; Bio Rad Labs.,
Hercules, CA).
 
Results
 
The Presentation of Three Distinct Peptide Determinants Within
HEL That Require Active Endocytic Processing Shows Differential
Dependence on Newly Synthesized Proteins.
 
Many previous
studies have shown varying sensitivities of class II antigen
presentation to metabolic inhibitors, or distinct requirements
for particular cell types, for new protein synthesis, or for Ii,
suggesting the existence of multiple distinct pathways for
antigen processing and presentation by class II molecules.
Most of these, however, have involved comparisons be-
tween different proteins or distinct MHC class II alleles. To
more systematically explore this issue, we have turned to a
well-studied model antigen. HEL contains three distinct
determinants (34-45, 46-61, and 116-129) that bind to the
same class II molecule, A
 
a
 
k
 
A
 
b
 
k
 
, with a different dependence
on the coexpression of Ii (19) or lysosome-dependent disul-
fide bond reduction and fragmentation of the HEL protein
(44, 45). We first verified that all three determinants require
pH -sensitive intracellular processing (Fig. 1). The lysoso-
motropic amine chloroquine inhibits the presentation of all
three determinants by normal B cell blasts (Fig. 1 
 
B
 
). Fur-
thermore, if these B cell APCs are chemically fixed before
antigen exposure, they present synthetic peptides and dena-
tured HEL, but not intact, nondenatured HEL (data not
shown). These results indicate that T cell recognition of all
three determinants requires active intracellular processing
of the native protein. Despite this, when BFA is used to
block export of newly synthesized proteins from the endo-
plasmic reticulum, only the presentation of HEL 46-61 is
strongly inhibited (Fig. 1 
 
C
 
). This suggests that presenta-
tion of HEL 34-45 and 116-129 may involve a pool of ma-
ture class II molecules.
 
The Role of Ii in the Presentation of HEL Determinants.
 
We next reexamined the Ii dependence of presentation of the
three determinants. The lack of a requirement for newly
synthesized proteins suggested that Ii-associated class II mole-
cules would not be required for presentation of 34-45 or
116-129, in contrast to 46-61. COS cells were transiently
transfected with plasmid constructs encoding I-A
 
k
 
 
 
a
 
 and
 
b
 
 chains or I-A
 
k
 
 plus mouse Ii 31, and the transfectants were
monitored for class II surface expression levels by FACS
 
Ò
 
.
All transfectant pools used in these experiments expressed
equivalent levels of A
 
k
 
 as detected with mAb H116.32 (data
not shown), in agreement with our earlier data showing
that in COS, Ii coexpression does not noticeably increase
surface levels of A
 
k
 
 (38). COS transfectants expressing A
 
k
Figure 1. The 34-45, 46-61, and 116-129 determinants in HEL all re-
quire endocytic processing for presentation, but only 46-61 requires
newly synthesized proteins. B lymphoblasts were incubated with the indi-
cated concentrations of HEL in standard medium for 6 h or with 50 mM
HEL for 6 h in the presence of the indicated concentrations of drug. The
B cells were then fixed and used as APCs with T hybridomas specific for
each determinant. IL-2 production at 24 h is presented as OD obtained
using an IL-2–specific capture ELISA. The data represent one of three in-
dependent experiments. 
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alone efficiently present 34-45 and 116-129, but not 46-61.
Cotransfection with Ii dramatically increases the presenta-
tion of 46-61 (Fig. 2 
 
A
 
), but has little effect on presentation
of 34-45 and 116-129 (Fig. 2, 
 
B
 
 and 
 
C
 
). Again, these data
are consistent with studies using rat-2 transfectants and the
differential requirement for protein export from the secre-
tory pathway for presentation of the three determinants.
 
Role of the Cytoplasmic Tails of A
 
a
 
k
 
 and A
 
b
 
k
 
 in Presentation
of the Three HEL Fragments.
 
In certain cells, leucine-based
targeting signals in the Ii cytoplasmic tail are important for
the endocytic accumulation of newly synthesized class II
molecules (4–9). However, this is not true in all cells, and
the localization of class II to late endocytic structures has
been observed in several cell expressing class II without Ii
(26–28). Pinet et al. have reported that presentation of a
hemagglutinin determinant by DR is independent of Ii,
but requires uncharacterized internalization signals in the
cytoplasmic tails of the class II 
 
a
 
 and 
 
b
 
 chains (31). Smiley
et al. (32) have also shown a role for class II cytoplasmic
tails in antigen presentation and suggested that a dileucine-
based motif in the 
 
b
 
 chain may be involved in this func-
tion. To assess whether signals in the cytoplasmic tails of
the A
 
k
 
 molecule itself are involved in the presentation of
34-45 or 116-129, RBLs were stably transfected with con-
structs expressing various combinations of wild-type A
 
k
 
 or
A
 
k
 
 tail deletion mutants with or without Ii, and clones with
comparable levels of surface class II and intracellular Ii se-
lected. As with COS and rat-2 cells, efficient presentation
of 46-61, but not 34-45 and 116-129, by wild-type Ak ex-
pressed by RBLs depends on Ii (Fig. 3). Although cells ex-
pressing wild-type Ak alone can effectively stimulate 34-45–
and 116-129–specific T cells after HEL exposure, truncation
of the b chain tail prevents this presentation. Examination
of presentation of the three determinants by cells with the
b tail deleted Ak coexpressed with Ii revealed that each de-
terminant has a distinctive combination of requirements for
either Ii or the b chain tail. The 46-61 and 34-45 determi-
nants are both presented well by cells expressing I-Ak with
a truncated b chain tail together with Ii, but Ii expression
does not rescue the ability of b tail deleted class II mole-
cules to present 116-129. Therefore, the efficient presenta-
tion of 46-61 requires Ii irrespective of the presence or ab-
sence of the class II b chain tail, presentation of 34-45
requires either intact class II tail or Ii and the class II b tail is
required for the presentation of 116-129 and this function
cannot be replaced by Ii. Similar data were obtained using
transiently transfected COS cells (data not shown).
The Dileucine Region Within the Cytoplasmic Tail of the
Class II b Chain Is Required for Effective Ii-independent Anti-
gen Presentation. In discussing their evidence that the class
II b chain tail contributes to effective antigen presentation,
Smiley et al. have noted the existence of a conserved dileu-
Figure 2. Only the 46-61 de-
terminant is highly dependent on
Ii coexpression with Ak for its ef-
fective presentation. COS cells
transfected with cDNA expres-
sion constructs encoding either
Ak or Ak and the p31 form of
mouse Ii were used as APCs
with the indicated concentra-
tions of HEL for stimulation of
T hybridomas specific for the
indicated determinants of HEL.
IL-2 production at 24 h is pre-
sented as OD obtained using an
IL-2–specific capture ELISA. The
data represent one of three inde-
pendent experiments.
Figure 3. Differential require-
ments for Ii coexpression and for
the cytoplasmic tail of the class II
Ab chain in the presentation of
distinct determinants of HEL.
RBLs stably transfected with
constructs encoding the indi-
cated Aak and Abk proteins with
or without Ii p31 were used as
APCs for mouse T hybridomas
specific for the indicated determi-
nants. IL-2 production at 24 h is
presented as OD obtained using
an IL-2–specific capture ELISA.
The data represent one of three
independent experiments.433 Zhong et al.
cine in this segment of the protein, and suggested that it may
be part of a targeting motif (32). We have independently
compared the sequences of multiple class II b chains from
various species, looking for highly conserved sequences and
also for sequences resembling either the known leucine- or
tyrosine-containing signals mediating endocytic protein tar-
geting. As shown in Table 1, like Smiley et al., we identi-
fied the same conserved dileucine near the COOH termi-
nus of the b chain, preceded by an invariant glycine, giving
rise to the sequence GLL that closely resembles one of the
two localization signals in Ii (GLI in the mouse). This se-
quence in class II is also spaced only one residue further
from the end of the transmembrane domain as compared to
the comparable Ii sequence; previous studies have shown
that the distance of a signal from the membrane can play an
important role in its traffic control function (46). To test
directly whether these dileucines are a critical part of a
functional targeting motif in the class II tail, a mutant
cDNA was prepared that encodes a complete Abk chain ex-
cept for substitution of the two cytoplasmic leucines with
alanines (bCTAA). This construct was stably transfected
into RBLs along with plasmids encoding wild-type Aak
chains, with or without the construct for Ii. The ability of
the transfected cells to present the three HEL determinants
was compared to the wild-type Ak transfectants (Fig. 4). Like
deletion of the entire b chain tail, substitution of the two
leucines with alanine prevents the presentation of 34-45
and 116-129 in cells lacking Ii, and Ii coexpression with
class II containing bCTAA can rescue presentation of 34-45
but not 116-129.
Replacement of the b Chain Cytoplasmic Leucines with Ala-
nines Delays, but does Not Prevent, Ak Internalization into En-
dosomes. Based on the results of Pinet et al. showing that
deletion of either the class II a or b tails precluded internal-
ization of surface DR (31), we expected that the bCTAA-
containing Ak molecules would fail to accumulate in the
endocytic pathway, thus accounting for the lack of effec-
tive presentation of the 34-45 determinant in the absence
of Ii. However, confocal immunofluorescence microscopy
unexpectedly revealed the steady state localization of class
II in a variety of endocytic structures, including lamp 11
compartments, in cells expressing mutant molecules with
either the b tail deletion or bCTAA (data not shown). This
suggested that either a recycling model for presentation of
these determinants was incorrect, or that the loss of pre-
senting function due to these mutations resulted from a
more subtle change in the trafficking of class II than re-
vealed by such staining studies. We therefore examined the
entry of mature surface class II molecules into endosomes
using surface-bound antibody as a probe. Cells expressing
wild-type Ak with or without Ii rapidly internalize a sub-
stantial fraction of antibody-bound surface class II; within 5
to 10 min of warming to 378C, distinct staining of small
vesicles is observed and accumulation of signal in larger ve-
sicular structures is readily apparent by 15 to 30 min (Fig. 5).
Table 1. Leucine-Based Motif in the Class II b Chain 
Cytoplasmic Tail
Species/protein Cytoplasmic tail sequence
Human DR RNQKGHSGLQPTGFLS
Human DQ RSQKGPQGPPPAGLLH
Chimp DR RNQKGHSGLQPTGFLS
Mouse I-A RSQKGPRGPPPAGLLQ
Mouse I-E RNQKGQSGLQPTGLLS
Rat I-A R-QKGPQGPPPAGLLQ
Rat I-E RSQKGNSGLQPTGLLN
Dog DR RNQKGHSGLQPTGLLS
Chicken RGQKGRPVAAAPGMLN
«
Mouse I-A RSQKGPRGPPPAGLLQ
Mouse Ii RSCREPERPRNGLIPLQEHNSILDRQDDM
Alignment of the sequences in the cytoplasmic tails of MHC class II b
chains of various species (63), and of mouse class II Ab and mouse Ii.
For Ii, the sequence is shown C®N from left to right because this is a
type II membrane protein shown in its proper orientation relative to
the membrane and the adjacent class II sequence. The double-headed
arrow points to an invariant glycine residue that precedes the conserved
leucine-containing pair of amino acids.
Figure 4. Mutation of the
conserved LL sequence at the
COOH terminus of the Ab
chain cytoplasmic tail eliminates
the ability of this protein to me-
diate Ii-independent presentation
of either the 34-45 or 116-129
determinants of HEL. RBLs sta-
bly transfected with constructs
encoding the indicated Aak and
Abk proteins with or without Ii
p31 were used as APCs for
mouse T hybridomas specific for
the indicated determinants. IL-2
production at 24 h is presented as
OD obtained using an IL-2–spe-
cific capture ELISA. The data
represent one of three indepen-
dent experiments.434 Tail Signal Control of MHC Class II Antigen Presentation
In contrast, cells expressing Ak containing either the tail-
deleted or double alanine mutant b chain show little evi-
dence of internalized class II at 10 min and only modest
staining of very small vesicles at 30 min. Cells expressing
class II molecules lacking both the b and a chain cytoplas-
mic regions show no detectable intracellular class II accu-
mulation using this method at up to 150 min of incubation
(data not shown), suggesting that the residual internaliza-
tion seen with the bCTAA–wild-type a combination may
depend on a separate, as yet uncharacterized, signal in the a
chain tail.
Differential Presentation of 34-45 and 116-129 Versus 46-
61 by Macrophages and B Cell Blasts, and Their Relationship to
Proteolytic Activity. The 34-45, 46-61, and 116-129 deter-
minants of HEL lie in very different locations in the folded
structure of the intact HEL protein, with 116-129 being
most superficial, 34-45 being partially buried, and 46-61
lying at the core of the protein in a structure maintained by
disulfide bonds. Presentation of the 46-61 determinant of
HEL requires the reducing environment found in lyso-
somes (44, 45) and this correlates with where newly syn-
thesized class II–Ii complexes accumulate before Ii diges-
tion and CLIP removal (10, 47–51). On the other hand,
the inability of Ii to rescue presentation of 116-129 in cells
expressing tail-mutated class II suggests that this determi-
nant may not be available in such highly acidic, dense, en-
docytic organelles. In this regard, Frosch et al. have re-
ported that IFN-g activated MF fail to present a particular
insulin determinant (52), although B cells from the same
mouse are fully competent to do so. This difference appears
to be related to the more rapid and complete digestion of in-
sulin by the MF, which prevents effective capture by class
II. Given the different locations of the three HEL determi-
nants in the native protein, one might expect that 116-129
and perhaps 34-45, but not 46-61, to be overdigested in
activated macrophages, as compared to the B cell blasts
used in the studies shown in Fig. 1. As shown in Fig. 6, this
is the case. IFN-g–activated macrophages are quite effec-
tive in presenting the 46-61 determinant, but inefficient in
presenting either the 34-45 or 116-129 determinants. If
chloroquine or leupeptin is added to HEL-exposed mac-
rophages before fixation, there is a paradoxical dose-depen-
dent gain in presentation of the 34-45 and 116-129 deter-
minants, but a decline in the presentation of 46-61.
Discussion
The various organelles comprising the endosomal/lyso-
somal pathway have distinct pHs, protease contents, and
capacities to promote protein unfolding (53). These prop-
erties and the rate of luminal content transfer among these
organelles also vary for cells of distinct tissue origin or state
of activation. These differences all affect the function of the
class II antigen presentation system by influencing the
availability of specific sequences within any given protein
for binding to MHC class II molecules in the same com-
partment. Likewise, heterogeneity in protein structure and
binding site occupancy also modify the capacity of class II
molecules to capture protein/peptide substrates in these or-
ganelles. In part, ensuring the presentation of diverse anti-
genic ligands is promoted by the simultaneous expression
of multiple class II proteins in the cells of a single individ-
ual. However, because the different proteins of pathogens
may vary from those that are highly sensitive to protease at-
tack to some requiring extremely harsh conditions for di-
gestion, it also makes sense that the immune system would
evolve the means to enable these polymorphic class II pro-
teins to sample several endocytic organelles for suitable li-
Figure 5. Deletion or mutation of the Ab cytoplasmic tail results in a
delayed rate of internalization of mature surface class II into the endocytic
pathway. RBL stable transfectants expressing Aak along with the indi-
cated Ab chains were bound to anti–class II mAbs in the cold, then
warmed to 378C for the indicated times. Cells were then permeabilized
and stained for mouse immunoglobulin and analyzed by confocal immu-
nofluorescence microscopy.
Figure 6. Differential presentation of the three HEL determinants by
IFN-g–activated macrophages and the effects of inhibitors of protein degra-
dation on this presentation. Peritoneal macrophages were cultured in IFN-g
for 48 h, and then exposed to the indicated concentrations of HEL for 6 h
or 50 mM HEL for 6 h with or without the indicated drugs. Cells were
then washed, fixed, and used as APCs for the appropriate T hybridomas. IL-2
production at 24 h is presented as OD obtained using an IL-2–specific cap-
ture ELISA. The data represent one of the three independent experiments.435 Zhong et al.
gands. The data presented in this paper suggest that two
different cohorts of MHC class II molecules sample endo-
cytic content in an overlapping pattern that permits ligand
capture from both early and late endocytic compartments.
The control of protein trafficking necessary for the opera-
tion of these two presentation pathways lies in related cyto-
plasmic leucine-based signals, one of which is characterized
in this study. However, it is the timing of binding site
availability that appears to actually distinguish where class II
molecules in each pathway most effectively acquire antigen.
Previous studies have shown that leucine-based motifs
within the cytoplasmic tail of Ii are essential for effective lo-
calization of newly synthesized class II–Ii complexes to late
endocytic/lysosomal organelles (7–9). These leucine-con-
taining signals are similar to others found in proteins such as
the TCR CD3g and d chains (54) and GLUT4 (55) that
also promote trafficking of the respective proteins to en-
docytic organelles. Ii proteolysis and removal is minimal
during passage through early endosomes, modest in late en-
dosomes, and extensive in a lysosome-like fraction (10) that
corresponds to the MIIC defined by immunoelectron mi-
croscopy (6). Class II molecules cannot bind a new ligand
until Ii is degraded and CLIP is removed or dissociated from
the class II binding site, in large part through the action of
DM that is concentrated in the MIIC by a distinct tyrosine-
containing motif (56). Therefore, Ii-associated, newly syn-
thesized class II molecules are most likely to participate pri-
marily in the presentation of determinants surviving until,
or first exposed in, this highly proteolytic, acidic environ-
ment. In accord with this, the 46-61 determinant of HEL,
which is located in the core of this globular protein and
protected by disulfide bonds, shows a strong dependence
on Ii for its presentation. This agrees with studies indicating
that the best presentation of this determinant occurs when
lysosome-like organelles with strong reducing capacity are
accessed by HEL (44, 45) and showing that this peptide has
a pH optimum of 5 for binding to Ak (57).
In contrast, two other determinants within the same HEL
molecule, at residues 34-45 and 116-129, show a very dif-
ferent behavior. Neither is well presented by activated
macrophages, and partial inhibition of protease activity im-
proves presentation of these determinants in such macro-
phages, but not in less proteolytically active B cell blasts.
Inhibition of the trafficking of newly synthesized proteins
had at best modest effects on the presentation of these de-
terminants and neither required Ii for their presentation.
Taken together, these data argue that both of these deter-
minants are available to a cohort of class II molecules distinct
from that associated with Ii. Because control experiments
showed that endocytic processing was involved, these data
suggested that exposure and capture of these regions of
HEL occurs in early endocytic compartments and involves
mature class II molecules. This in turn led to an attempt to
understand how a surface pool of mature class II molecules
could gain access to such endocytic organelles. Sequence
alignment revealed a highly conserved GLL motif in the
tail of class II b chains which, when deleted or altered to
GAA, resulted in class II molecules unable to present the
34-45 or 116-129 determinants in the absence of Ii. The
variable effect of mutation at these leucines on presentation
of distinct antigenic determinants is consistent with the ear-
lier suggestion by Smiley et al. (32) that a signal containing
these residues could play a role in differential antigen pre-
sentation by tailless versus wild-type class II molecules.
The steady state distribution of class II in transfectants with
wild-type or signal-minus class II molecules did not differ
grossly. Internalization experiments, however, revealed a
clear effect of the mutations, namely a significant delay in
the rate of internalization of surface class II into the endo-
cytic pathway. Previous results have shown that class II bind-
ing sites lose their function rapidly at physiological temper-
ature in the absence of ligand engagement (3, 58, 59). If the
major pool of class II sites involved in acquisition of deter-
minants such as HEL 116-129 become empty on the cell
surface before internalization, delayed uptake would result
in such molecules becoming incapable of peptide binding
by the time they reached the site of antigen availability. Al-
ternatively, the class II molecules involved in HEL 116-129
presentation may only shed their original peptide upon ex-
posure to the mildly acidic pH of early endosomes, where-
upon they would be immediately available to bind new
ligand. Substantially decreasing the pool of such molecules
reaching the endocytic pathway at any point in time could
then markedly reduce antigen presentation. Both of these
effects may in fact contribute to the functional defect ob-
served with the mutant class II chains lacking the GLL mo-
tif. This model also can account for the recent findings of
Smiley et al. (60), who demonstrated an increased density of
CLIP–class II complexes on cells expressing class II mole-
cules with a b chain whose cytoplasmic tail had been trun-
cated. Because CLIP release is facilitated at acidic pH (61),
decreased internalization due to the b mutation would al-
low such complexes to accumulate to a higher level on the
plasma membrane, rather than dissociating upon internal-
ization and recycling. The decrease we observed in class II
internalization rate without a loss of steady-state localiza-
tion in endocytic organelles following mutation of a dileu-
cine signal is also very similar to results obtained in studies
of the GLUT4 glucose transporter (55).
The timing of binding site availability appears to play a
predominant role in dictating which set of determinants is
presented by which cohort of class II molecules. The bind-
ing sites of Ii-associated class II become available mainly in
the MIIC via the action of cathepsins and DM, and this bi-
ases these dimers for capture of those determinants able to
survive transport through earlier endocytic compartments.
These same class II molecules are ineffective in the capture
of determinants present only in early endosomes because
they do not have an accessible binding site in that location.
Conversely, mature class II molecules, using a very homol-
ogous targeting signal to traffic to the same or a similar set
of early and late endocytic organelles, primarily bind those
ligands available in early endocytic compartments because
the binding site is accessible there. Some determinants such
as 34-45 appear to be available in more than one location,
permitting capture by class II via either pathway.436 Tail Signal Control of MHC Class II Antigen Presentation
The added breadth of determinants presented to CD41
T cells through use of a recycling pathway has obvious ad-
vantages for the immune system. Viruses enter cells by fus-
ing with or disrupting either plasma or early endosomal
membranes. The relevant viral proteins often undergo
structural changes and remain in these membranes when the
viral genome enters the cytosol (62). Such refolded proteins
may be highly susceptible to proteolysis shortly after viral
entry, and the presentation of determinants derived from these
proteins would help elicit a T cell response at the earliest
time after viral infection. Data consistent with this sugges-
tion come from the work of Pinet et al. (31), who showed
that a determinant from influenza hemagglutinin was pre-
sented in an Ii-independent, class II tail-dependent manner.
Another rationale besides sensitivity to proteolysis for such
a pathway is the capture of ligands unable to bind tightly to
class II at the highly acidic pH of the MIIC.
The results presented here, together with the recent
study of Pinet et al. (31) help rationalize a contradictory lit-
erature concerning the role of newly synthesized versus
mature class II molecules and of Ii in class II presentation to
T cells. They also emphasize the important differences in
processing and presentation of the same protein by different
cell types, as evidenced by the inability of activated mac-
rophages to present 34-45 or 116-129 without addition of
an inhibitor of lysosomal function. The demonstration that
cytoplasmic signals in the class II b chain tail control the
rate of class II entry into the endocytic pathway for capture
of only a subset of antigenic determinants provides an ex-
planation for earlier reports of a variable influence of class II
tail deletion on antigen presentation (29, 30). Our evidence
that a leucine-based motif is involved in this endocytic tar-
geting emphasizes the importance of this motif in immuno-
logical function, especially as concerns T cell antigen rec-
ognition. On the other hand, the rather modest effect of
elimination of the class II tail motif on in vivo immunity to
a range of pathogens (32) raises some question as to the
physiologic significance of this Ii-independent pathway.
However, the organisms studied in this report were prima-
rily those resident in the endocytic compartment itself, and
not viruses, for which we argue the recycling pathway may
have a special importance. It is also the case that the studies
conducted here have not been performed in typical he-
matopoietic antigen presenting cells. This clearly leaves to
future studies a fuller determination of the roles of the two
class II pathways defined here in the protective functions of
the immune system.
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